Medivir to present at the ABGSC Life Science Summit
News provided by
Share this article
STOCKHOLM, May 25, 2021 /PRNewswire/
Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will present at the virtual meeting ABGSC Life Science Summit, today, May 25.
The company will be represented by
Magnus Christensen, interim CEO, and Fredrik Öberg, Chief Scientific Officer.
The presentation will be available after the seminar on Medivirs website; www.medivir.com.
For additional information, please contact
Magnus Christensen, interim CEO and CFO
Telephone: +46 8 5468 3100
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat li
Share this article
STOCKHOLM, May 25, 2021 /PRNewswire/
Medivir AB (Nasdaq Stockholm: MVIR) today announced the details of its upcoming phase 1/2a combination study with the company s leading candidate drug, MIV-818, against liver cancer. The unique mechanism of action of MIV-818 makes it attractive to be combined with a multitude of other targeted and non-targeted drugs for the treatment of hepatocellular carcinoma. In the upcoming combination study, MIV-818 will be administered in two combinations, either with lenvatinib, a tyrosine kinase inhibitor or pembrolizumab, an anti-PD-1 check-point inhibitor.
The planned trial will be an open-label, multi-center phase 1/2a study starting with a dose escalation part to establish the recommended phase 2 dose (RP2D). This is followed by the expansion study (phase 2a) with an initial evaluation of the safety and efficacy of the combination of MIV-818 with lenvatinib or pembrolizumab. The study will include patients with hepatocellular
Share this article
STOCKHOLM, May 20, 2021 /PRNewswire/
Medivir AB (Nasdaq Stockholm: MVIR) today announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC). The primary objective of the study was to assess the effects of topical remetinostat on biopsy-proven SCC and SCC in situ tumors. This clinical study was conducted at the Stanford University School of Medicine in California, USA under the leadership of the principal investigator, Dr Kavita Sarin. Medivir is providing remetinostat drug supply for this study, and has full access to, and the rights to use, all clinical data after the study is complete.
Resolutions at the Annual General Meeting in Medivir on 5 May 2021
News provided by
Share this article
HUDDINGE, Sweden, May 5, 2021 /PRNewswire/
Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director
The annual general meeting in Medivir Aktiebolag (publ) on 5 May 2021 resolved to approve the profit and loss accounts and balance sheets for the financial year 2020. The persons who had been board members and managing directors were discharged from liability with respect to their respective management of the company for the financial year 2020.
Appropriation of the company s profit or loss
Medivir to participate at the Kempen Life Sciences Conference
News provided by
Share this article
Medivir AB (Nasdaq Stockholm: MVIR)
today announces that the company will participate at the virtual meeting Kempen Life Sciences Conference - 2021 Thematic Virtual Series, on April 21.
The presentation will be available via Medivirs website; www.medivir.com.
For additional information, please contact
Yilmaz Mahshid, CEO
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.